CV Sciences, Inc. Annual Report: A Plain-English Guide

This guide breaks down how CV Sciences, Inc. performed this year. My goal is to simplify complex financial filings so you can decide if this company fits your investment strategy.

1. What does this company do?

CV Sciences is a health and wellness company expanding beyond its roots in CBD. While the +PlusCBD™ line remains their primary source of income, they are diversifying into two new areas:

• Plant-based foods: They operate Cultured Foods™ in Europe and Lunar Fox™ in the U.S., targeting the growing market for vegan, sustainable protein.
• Manufacturing: Through their acquisition of Elevated Softgels, they now produce their own supplements. This allows them to handle orders for other companies, creating a flexible income stream that stabilizes cash flow by using their existing facilities.

2. Financial Snapshot: The Bottom Line

The company is in "turnaround mode." They are not yet profitable, but they are losing significantly less money than last year.

• Sales are down: Revenue fell about 12% (from $15.7 million in 2023 to $13.8 million in 2024). This was due to a shrinking CBD retail market and a shift away from older, less profitable products.
• Better efficiency: Even with lower sales, the company kept more of every dollar. Their profit margin after production costs improved from 45.6% to 49%. This is largely thanks to Elevated Softgels, which reduced their reliance on outside manufacturers.
• Shrinking losses: Their total loss dropped from $2.4 million in 2023 to $0.9 million in 2024.
• Innovation: A bright spot is that 39% of 2024 revenue came from products launched in the last two years. This shows their new wellness and plant-based strategy is gaining traction.

3. Major Wins and Strategic Shifts

• Cost Cutting: The company aggressively trimmed expenses. They cut operating costs by 17.5% by reducing staff, optimizing marketing, and streamlining administrative overhead.
• The "Dormant" Drug Program: They hold patents for a CBD-nicotine treatment for tobacco addiction. However, this program is currently on hold. The company is prioritizing cash for high-growth consumer products rather than expensive, long-term FDA clinical trials.
• Quality Control: They use independent labs to test every ingredient before and after it enters their facility. This is a competitive advantage in an industry often criticized for inconsistent purity.

4. Key Risks: The "Regulatory Cliff"

This is the most important factor for you to watch:

• The November 2026 Deadline: The 2018 Farm Bill, which legalized hemp, faces expiration. New federal rules are changing how "hemp" is defined. Many products CV Sciences currently sells could become illegal or face strict new oversight after November 12, 2026, unless Congress passes new laws.
• Financial Fragility: As of late 2024, the company held about $0.8 million in cash. Their current credit agreements prevent them from paying dividends. If their new products do not break even within 18 months, they may need to issue more shares to raise money, which would reduce your ownership percentage.

Investor Takeaway: CV Sciences is currently a high-risk, high-reward play. They are successfully cutting costs and proving they can innovate with new product lines, but their survival depends on navigating a difficult regulatory environment and managing a tight cash balance. Before investing, consider whether you are comfortable with the uncertainty surrounding the 2026 federal hemp regulations.